Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
Clinical trial NCT01989585 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT01989585
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-24
- Primary completion
- 2027-12-31
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.